This study is for patients that have been diagnosed with indolent B cell non-Hodgkin lymphoma and your disease returned or did not improve at all after receiving one or more treatments containing rituximab.The investigational drug in this study is ALT-803. The purpose of this research study is to test standard rituximab with different doses of the study drug, ALT-803, to see which dose is safer in people. Participants can expect to be in this study for 36 weeks and have evaluations of your disease for up to 5 years.
This study is for patients that have been diagnosed with acute myelogenous leukemia (AML) . The investigational drug in this study is AG-120. The purpose of this study is to identify and test the highest dose of AG-120 that can be given safely. Participants can expect to be in the study for as long as the study doctor feels it is in the participants best interest.
The goal of this pilot study is to determine if, in treatment-seeking substance dependent individuals, ten sessions of continuous theta burst transcranial magnetic brain stimulation (cTBS) over a brain region involved in craving (medial prefrontal cortex) can lower an individual's craving and brain response to drug-related cues. This study involves a screening visit, followed by one MRI visit, followed by ten cTBS treatment visits on consecutive days. There will be three follow-up MRI visits: the first will immediately follow completion of a 28-day outpatient treatment program, while the second and third will be one month and two months post-treatment.
Biases in cognitive processing of drug-related stimuli are central to the maintenance of addiction and contribute to poor treatment outcome. This study will evaluate how people who frequently use marijuana respond to marijuana cues, and if a computerized task affects this response. During the two week study period participants will engage in four computer task sessions, and response to marijuana cues will be assessed directly before and after the two-week study period. Two weeks after the last study visit, marijuana cue response and computer task performance will again be assessed. Marijuana use will be tracked throughout the study and follow-up periods.
You may be eligible if you:
Are between the ages of 18 and 65.
Are willing to provide informed consent.
Eligible participants may receive compensation.
Our recently completed study has provided the first evidence that administration of the medication propranolol, following exposure to cocaine cues, can alter drug-associated memories and reduce craving and other drug cue-elicited responses in cocaine addicted persons. The proposed research will use two methods to increase the memory altering effects of propranolol observed in our recently completed study, and document lasting effects not only on craving and cue-elicited reactions, but also on cocaine use. Positive findings will set the stage for a formal clinical trial that could lead to significantly improved treatment outcomes for this treatment-resistant addiction.
Treatment of children ? 3 and < 22 years for newly diagnosed medulloblastoma with clinical and molecular risk directed therapy. Innovations to contemporary medulloblastoma therapy include reduced dose cyclophosphamide, reduced dose radiation therapy for low risk medulloblastoma, and use of novel therapies targeted toward the specific molecular subgroups of the disease.
The purpose of this research study is to test the safety, effectiveness and tolerability of an investigational drug called DAS181 on subjects with a very weak immune system who are diagnosed with PIV. An investigational drug is one that is not approved by the United States Food and Drug Administration (FDA). DAS181 can be administered as a reconstituted dry powder that is breathed into the respiratory tract (nose, throat and lungs) using a liquid aerosol spray administered using a nebulizer. A nebulizer is an electrically powered machine that turns liquid medication into a mist so that it can be breathed directly into the lungs through a face mask or mouthpiece.
This study is for subjects who have been diagnosed with head and neck cancer and are being treated with radiation therapy and chemotherapy. This treatment is expected to irritate the mouth and throat and cause a condition called oral mucositis, which may cause pain and difficulty swallowing. The investigational drug in this study is an oral rinse called BRILACIDIN. It is being studied to see if it can prevent or decrease the occurrence of oral mucositis. The purpose of this study is to see if BRILACIDIN can prevent or decrease the occurrence of oral mucositis. Participants can expect to be in this study for 14-15 weeks.
Non-alcoholic steatohepatitis (NASH) is a chronic inflammatory disease that progressively leads to fibrosis and eventually cirrhosis (scarring of the liver). Currently, there are no medical therapies for NASH or liver fibrosis. The purpose of this study is to determine if an investigational drug, GR-MD-02, can reverse the scarring in the liver and heal cirrhosis.
This is an open-label rollover study for subjects who have participated in 661-103, 661-106 or 661-109
This study will evaluate the long term safety and effects of treatment with VX-661 in combination with ivacaftor over 100 weeks in subjects with Cystic Fibroisis 12-years-old and older who are heterozygous or homeozygous for the F508del-CFTR mutation.